Search

Your search keyword '"Marano, Laura"' showing total 13 results
Start Over Author "Marano, Laura" Search Limiters Peer Reviewed
13 results on '"Marano, Laura"'

8. "Covid arm": Abnormal side effect after Moderna COVID‐19 vaccine.

Author

Picone, Vincenzo, Martora, Fabrizio, Fabbrocini, Gabriella, and Marano, Laura

Subjects
COVID-19 vaccines, COVID-19, VACCINATION complications
Abstract

Several cutaneous reactions to Moderna (83%) or Pfizer (17%) COVID-19 vaccines were reported by McMahon et al. for 414 unique patients.1 The most common cutaneous reaction was delayed large local reaction, followed by local injection site reactions, urticaria, morbilliform eruptions, erythromelalgia, and pernio/chilblains. Dear Editor In December 2020 the FDA authorized Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. We report two cases of "COVID arm": a localized erythematous reaction at the injection site after the first administration of Moderna COVID-19 vaccine.2 None of them had COVID-19 infection symptoms prior to their COVID-19 vaccinations and the onset of their skin rash. [Extracted from the article]

Published
2022
Full Text
View/download PDF

10. TWITTER.

Author

CHOUINARD, EDITH, Mendes, Shawn, Jobin, Jean-Thomas, Reinhart, Lili, Stréliski, Léa, Marano, Laura, and Condor, Lana

Published
2019

11. Say WHAT?

Author

MARANO, LAURA

Published
2019

13. Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study

Author

Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio, Megna, Matteo, Ruggiero, Angelo, Battista, Teresa, Marano, Laura, Cacciapuoti, Sara, and Potestio, Luca

Subjects
anti-IL23, General Medicine, risankizumab, biologic, psoriasi, psoriasis, biologics
Abstract

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been recently approved by the EMA and the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Its efficacy and safety have been reported by clinical trials and real-life studies. However, even if long-term data from trials have already been reported (up to 172 weeks), data on long-term real-life experiences are still limited. The aim of our study was to investigate the long-term (2 years) efficacy and safety of risankizumab for psoriasis management in a real-life setting. A monocentric retrospective study was performed, enrolling 168 patients affected by moderate to severe psoriasis who were undergoing treatment with risankizumab. Psoriasis severity and safety outcomes were evaluated at each follow-up visit (week 16, week 28, week 52, week 88, week 104). A statistically significant reduction of psoriasis severity scores was reported from week 16 and was maintained up to week 104. Moreover, interesting results in terms of safety have been collected, without any serious adverse events registered. Our long-term real-life monocentric retrospective study confirmed the efficacy and safety of risankizumab up to 104 weeks of treatment. However, further studies are required to confirm our results and to increase available data to establish the best evidence-based biologic selection algorithm.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results